We are live on ! Find out more

vTv Therapeutics

VTVT

Market cap $121M

30.55 USD

+0.09

0.3%

At close Updated Oct 13, 10:41 AM EDT

1 day

0.3%

5 days

2%

1 month

-2.83%

3 months

-3.26%

6 months

-17.65%

Year to date

-22.85%

1 year

40.07%

5 years

-49.75%

10 years

-88.5%

About: vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Employees: 26

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 20, 2026, at 2:30 PM ET.

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

Milestone advances Phase 3 program toward topline results expected in mid 2027 Milestone advances Phase 3 program toward topline results expected in mid 2027

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics to Participate in September Investor Conferences

HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September:

vTv Therapeutics to Participate in September Investor Conferences

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D HIGH POINT, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 23,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 12,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Price charts implemented using Lightweight Charts™